日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols

癌症免疫治疗学会 (SITC) 关于免疫治疗临床方案关键生物标志物的共识声明

Cottrell, Tricia R; Lotze, Michael T; Ali, Alaa; Bifulco, Carlo B; Capitini, Christian M; Chow, Laura Q M; Cillo, Anthony R; Collyar, Deborah; Cope, Leslie; Deutsch, Julie Stein; Dubrovsky, Genia; Gnjatic, Sacha; Goh, Denise; Halabi, Susan; Kohanbash, Gary; Maecker, Holden T; Maleki Vareki, Saman; Mullin, Sarah; Seliger, Barbara; Taube, Janis; Vos, Wim; Yeong, Joe; Anderson, Kristin G; Bruno, Tullia C; Chiuzan, Codruta; Diaz-Padilla, Ivan; Garrett-Mayer, Elizabeth; Glitza Oliva, Isabella C; Grandi, Paola; Hill, Elizabeth G; Hobbs, Brian P; Najjar, Yana G; Pettit Nassi, Phyllis; Simons, Virgil H; Subudhi, Sumit K; Sullivan, Ryan J; Takimoto, Chris H

Biomarkers predictive of response to pembrolizumab in head and neck cancer

预测头颈癌患者对帕博利珠单抗治疗反应的生物标志物

Pfister, David G; Haddad, Robert I; Worden, Francis P; Weiss, Jared; Mehra, Ranee; Chow, Laura Q M; Liu, Stephen V; Kang, Hyunseok; Saba, Nabil F; Wirth, Lori J; Sukari, Ammar; Massarelli, Erminia; Ayers, Mark; Albright, Andrew; Webber, Andrea L; Mogg, Robin; Lunceford, Jared; Huang, Lingkang; Cristescu, Razvan; Cheng, Jonathan; Seiwert, Tanguy Y; Bauml, Joshua M

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

肿瘤突变负荷、炎症基因表达谱和PD-L1表达对头颈部鳞状细胞癌患者帕博利珠单抗治疗反应的影响

Haddad, Robert I; Seiwert, Tanguy Y; Chow, Laura Q M; Gupta, Shilpa; Weiss, Jared; Gluck, Iris; Eder, Joseph P; Burtness, Barbara; Tahara, Makoto; Keam, Bhumsuk; Kang, Hyunseok; Muro, Kei; Albright, Andrew; Mogg, Robin; Ayers, Mark; Huang, Lingkang; Lunceford, Jared; Cristescu, Razvan; Cheng, Jonathan; Mehra, Ranee

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

CheckMate 017 和 057 随机 III 期试验的五年结果:纳武利尤单抗与多西他赛治疗既往接受过治疗的非小细胞肺癌

Borghaei, Hossein; Gettinger, Scott; Vokes, Everett E; Chow, Laura Q M; Burgio, Marco Angelo; de Castro Carpeno, Javier; Pluzanski, Adam; Arrieta, Oscar; Frontera, Osvaldo Arén; Chiari, Rita; Butts, Charles; Wójcik-Tomaszewska, Joanna; Coudert, Bruno; Garassino, Marina Chiara; Ready, Neal; Felip, Enriqueta; García, Miriam Alonso; Waterhouse, David; Domine, Manuel; Barlesi, Fabrice; Antonia, Scott; Wohlleber, Markus; Gerber, David E; Czyzewicz, Grzegorz; Spigel, David R; Crino, Lucio; Eberhardt, Wilfried Enst Erich; Li, Ang; Marimuthu, Sathiya; Brahmer, Julie

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

一项针对既往未接受过EGFR TKI治疗且EGFR突变阳性的局部晚期/转移性非小细胞肺癌患者的吉非替尼联合度伐利尤单抗的I期研究

Creelan, Benjamin C; Yeh, Tammie C; Kim, Sang-We; Nogami, Naoyuki; Kim, Dong-Wan; Chow, Laura Q M; Kanda, Shintaro; Taylor, Rosemary; Tang, Weifeng; Tang, Mei; Angell, Helen K; Roudier, Martine P; Marotti, Marcelo; Gibbons, Don L

Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer

epacadostat联合atezolizumab治疗既往接受过治疗的晚期非小细胞肺癌患者的I期研究

Hellmann, Matthew D; Gettinger, Scott; Chow, Laura Q M; Gordon, Michael; Awad, Mark M; Cha, Edward; Gong, Xiaohua; Zhou, Gongfu; Walker, Chris; Leopold, Lance; Heist, Rebecca S

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC

FIR:一项针对PD-L1阳性非小细胞肺癌患者的阿特珠单抗II期开放标签研究的疗效、安全性和生物标志物分析

Spigel, David R; Chaft, Jamie E; Gettinger, Scott; Chao, Bo H; Dirix, Luc; Schmid, Peter; Chow, Laura Q M; Hicks, Rodney J; Leon, Larry; Fredrickson, Jill; Kowanetz, Marcin; Sandler, Alan; Funke, Roel; Rizvi, Naiyer A

A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma

AZD1775联合新辅助每周多西他赛和顺铂治疗头颈部鳞状细胞癌的I期临床试验

Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C; Raju, Sharat; Diab, Ahmed; Harbison, R Alex; Konnick, Eric Q; Mugundu, Ganesh M; Santana-Davila, Rafael; Martins, Renato; Futran, Neal D; Chow, Laura Q M

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

帕博利珠单抗治疗复发/转移性头颈部鳞状细胞癌的疗效和安全性:KEYNOTE-012研究长期随访后的汇总分析

Mehra, Ranee; Seiwert, Tanguy Y; Gupta, Shilpa; Weiss, Jared; Gluck, Iris; Eder, Joseph P; Burtness, Barbara; Tahara, Makoto; Keam, Bhumsuk; Kang, Hyunseok; Muro, Kei; Geva, Ravit; Chung, Hyun Cheol; Lin, Chia-Chi; Aurora-Garg, Deepti; Ray, Archana; Pathiraja, Kumudu; Cheng, Jonathan; Chow, Laura Q M; Haddad, Robert

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)

Atezolizumab 作为一线或后续疗法治疗程序性死亡配体 1 选择的晚期非小细胞肺癌患者的 II 期试验 (BIRCH)

Peters, Solange; Gettinger, Scott; Johnson, Melissa L; Jänne, Pasi A; Garassino, Marina C; Christoph, Daniel; Toh, Chee Keong; Rizvi, Naiyer A; Chaft, Jamie E; Carcereny Costa, Enric; Patel, Jyoti D; Chow, Laura Q M; Koczywas, Marianna; Ho, Cheryl; Früh, Martin; van den Heuvel, Michel; Rothenstein, Jeffrey; Reck, Martin; Paz-Ares, Luis; Shepherd, Frances A; Kurata, Takayasu; Li, Zhengrong; Qiu, Jiaheng; Kowanetz, Marcin; Mocci, Simonetta; Shankar, Geetha; Sandler, Alan; Felip, Enriqueta